Evolva Holding SA (ELVAF)
USD 0.9
(0.0%)
USD 0.9
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 9.43 Million CHF | -73.25% |
| 2022 | 15.53 Million CHF | 57.32% |
| 2021 | 9.87 Million CHF | 30.99% |
| 2020 | 7.54 Million CHF | -34.97% |
| 2019 | 11.59 Million CHF | 29.82% |
| 2018 | 8.93 Million CHF | 30.47% |
| 2017 | 6.84 Million CHF | -21.73% |
| 2016 | 8.74 Million CHF | -6.93% |
| 2015 | 9.39 Million CHF | -12.52% |
| 2014 | 10.74 Million CHF | 23.41% |
| 2013 | 8.7 Million CHF | 24.12% |
| 2012 | 7.01 Million CHF | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 Q2 | 4.45 Million CHF | 100.0% |
| 2023 Q4 | -147.95 Thousand CHF | 0.0% |
| 2023 Q3 | -147.95 Thousand CHF | -103.32% |
| 2023 FY | 4.15 Million CHF | -73.25% |
| 2023 Q1 | 2.22 Million CHF | -69.93% |
| 2022 FY | 15.53 Million CHF | 57.32% |
| 2022 Q3 | 3.7 Million CHF | -54.49% |
| 2022 Q4 | 7.4 Million CHF | 100.0% |
| 2022 Q2 | 8.13 Million CHF | 100.0% |
| 2022 Q1 | 4.06 Million CHF | 16.14% |
| 2021 Q1 | 3.18 Million CHF | -10.88% |
| 2021 Q2 | 6.37 Million CHF | 100.0% |
| 2021 FY | 9.87 Million CHF | 30.99% |
| 2021 Q3 | 1.75 Million CHF | -72.53% |
| 2021 Q4 | 3.5 Million CHF | 100.0% |
| 2020 Q2 | 3.96 Million CHF | 100.0% |
| 2020 Q4 | 3.57 Million CHF | 100.0% |
| 2020 Q1 | 1.98 Million CHF | -62.11% |
| 2020 Q3 | 1.78 Million CHF | -54.88% |
| 2020 FY | 7.54 Million CHF | -34.97% |
| 2019 Q4 | 5.22 Million CHF | 100.0% |
| 2019 Q3 | 2.61 Million CHF | -58.92% |
| 2019 Q2 | 6.36 Million CHF | 100.0% |
| 2019 Q1 | 3.18 Million CHF | 24.2% |
| 2019 FY | 11.59 Million CHF | 29.82% |
| 2018 Q2 | 1.9 Million CHF | 0.0% |
| 2018 Q3 | 2.56 Million CHF | 34.63% |
| 2018 FY | 8.93 Million CHF | 30.47% |
| 2018 Q4 | 2.56 Million CHF | 0.0% |
| 2018 Q1 | 1.9 Million CHF | 17.91% |
| 2017 Q3 | 1.61 Million CHF | -10.75% |
| 2017 Q4 | 1.61 Million CHF | 0.0% |
| 2017 FY | 6.84 Million CHF | -21.73% |
| 2017 Q2 | 1.8 Million CHF | 0.0% |
| 2017 Q1 | 1.8 Million CHF | -38.66% |
| 2016 Q3 | 2.94 Million CHF | 60.34% |
| 2016 FY | 8.74 Million CHF | -6.93% |
| 2016 Q1 | 1.83 Million CHF | -27.73% |
| 2016 Q2 | 1.83 Million CHF | 0.0% |
| 2016 Q4 | 2.94 Million CHF | 0.0% |
| 2015 Q1 | 4.13 Million CHF | 43.78% |
| 2015 Q4 | 2.54 Million CHF | 0.0% |
| 2015 Q3 | 2.54 Million CHF | -38.5% |
| 2015 FY | 9.39 Million CHF | -12.52% |
| 2015 Q2 | 4.13 Million CHF | 0.0% |
| 2014 FY | 10.74 Million CHF | 23.41% |
| 2014 Q3 | 2.87 Million CHF | 15.34% |
| 2014 Q1 | 2.49 Million CHF | 5.54% |
| 2014 Q2 | 2.49 Million CHF | 0.0% |
| 2014 Q4 | 2.87 Million CHF | 0.0% |
| 2013 Q4 | 2.36 Million CHF | 0.0% |
| 2013 FY | 8.7 Million CHF | 24.12% |
| 2013 Q1 | 1.98 Million CHF | 13.68% |
| 2013 Q2 | 1.98 Million CHF | 0.0% |
| 2013 Q3 | 2.36 Million CHF | 18.83% |
| 2012 Q4 | 1.74 Million CHF | 0.0% |
| 2012 Q3 | 1.74 Million CHF | 0.0% |
| 2012 FY | 7.01 Million CHF | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -1450.931% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -2200.976% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Evofem Biosciences, Inc. | 18.21 Million USD | 48.195% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -12363.42% |
| Biomind Labs Inc. | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | 99.936% |
| CytoDyn Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -388.499% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -3889.601% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | 92.324% |
| SQZ Biotechnologies Company | 21.47 Million USD | 56.058% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -9433.709% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | 40.165% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -14258.873% |
| Mesoblast Limited | 5.9 Million USD | -59.909% |
| Marizyme, Inc. | 645.81 Thousand USD | -1361.39% |
| Genus plc | 668.8 Million USD | 98.589% |
| Pharming Group N.V. | 245.31 Million USD | 96.153% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -12195.046% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -23782.281% |
| MultiCell Technologies, Inc. | 49.32 USD | -19135747.526% |
| ONE Bio Corp. | 52.29 Million USD | 81.953% |
| RVL Pharmaceuticals plc | 49.72 Million USD | 81.018% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | 68.112% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -1592.241% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -13382.571% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -1333.227% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| Enzolytics Inc. | 52.79 Thousand USD | -17775.975% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | 99.23% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -6629.653% |
| Genscript Biotech Corporation | 839.52 Million USD | 98.876% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -53459.957% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -845.931% |
| EV Biologics, Inc. | 48.9 Thousand USD | -19200.204% |
| Q BioMed Inc. | 284.35 Thousand USD | -3219.055% |
| Capstone Therapeutics Corp. | 48.35 Million USD | 80.482% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | 93.496% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 16.68 Million USD | 43.437% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -944624.725% |
| Resverlogix Corp. | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -1428.676% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -3889.601% |
| Affymax, Inc. | 1.36 Million USD | -589.394% |
| Itoco Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -21.168% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -1892.232% |
| SYBLEU INC | 11.69 Thousand USD | -80592.544% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -72498.462% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -23772.616% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -183.417% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -41.602% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -808.354% |
| Gelesis Holdings, Inc. | 25.76 Million USD | 63.373% |
| CSL Limited | 14.8 Billion USD | 99.936% |
| Cellectis S.A. | 755 Thousand USD | -1150.04% |